Product
Sinovac
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
Randomized Controlled Trial to Assess the Immunogenicity and Safety of Full Versus Fractional Dose of Pfizer/BioNTech, AstraZeneca, and Sinovac COVID-19 Vaccines Given as a Booster Dose at Least 6 Months After Primary Vaccination Series or PCR-confirmed Infection With SARS-CoV-2 in Healthy AdultsStatus: Completed, Estimated PCD: 2023-07-28